Immuron Ltd
IMC
Company Profile
Business description
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact
Chapman Street
Unit 10, 25-37
Blackburn North
MelbourneVIC3130
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.30 | 5.70 | 0.06% |
| CAC 40 | 7,754.55 | 16.13 | 0.21% |
| DAX 40 | 23,934.13 | 144.02 | 0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,823.20 | 48.51 | 0.55% |
| HKSE | 23,921.81 | 148.13 | -0.62% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,730.16 | 55.74 | -0.14% |
| NZX 50 Index | 12,753.40 | 48.92 | 0.39% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,598.40 | 2.60 | 0.03% |
| SSE Composite Index | 3,475.24 | 14.09 | 0.41% |